Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Amgen (AMGN) Stock Price & Analysis
5,553 Followers
AMGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$206.75 - $327.16
Previous Close$300.3
Volume2.86M
Average Volume (3M)2.86M
Market Cap
$161.09B
Enterprise Value$215.40B
Total Cash (Recent Filing)$9.71B
Total Debt (Recent Filing)$64.02B
Price to Earnings (P/E)42.8
Beta0.46
Next Earnings
Jul 30, 2024EPS Estimate
$4.98Next Dividend Ex-Date
May 16, 2024Dividend Yield2.88%
Share Statistics
EPS (TTM)6.99
Shares Outstanding536,434,692
10 Day Avg. Volume3,417,009
30 Day Avg. Volume2,861,837
Standard Deviation0.07
R-Squared0.19
Alpha0.00602
Financial Highlights & Ratios
Price to Book (P/B)-3.57
Price to Sales (P/S)21.63
Price to Cash Flow (P/CF)74.70
P/FCF Ratio36.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.29
Enterprise Value/Gross Profit10.91
Enterprise Value/Ebitda17.69
Forecast
1Y Price Target
$321.29Price Target Upside4.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Amgen News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAMGN delivered solid financial results, driven by volume growth contributing to significant total revenue.
Product Pipeline ProgressManagement's announcement to progress MariTide into phase 3 for obesity and related disorders, as well as phase 2 for diabetes, is encouraging.
Stock Price Target IncreaseAnalyst raises the price target on the stock due to management's optimistic outlook on MariTide for obesity and diabetes.
Bears Say
Drug Efficacy And ApprovalFinancials were ok but the punchline came in management's encouraging characterization of MariTide interim Phase 2 data, although no data were actually provided.
Earnings And Financial PerformanceExpected biosimilar competition and increased R&D spending are key factors in the reduced earnings projection for 2025.
Product Sales And Market CompetitionCybersecurity issues significantly impacted Otezla prescriptions.
---
Ownership Overview
1.08% Insiders
21.40% Mutual Funds
32.12% Other Institutional Investors
45.40% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $206.75 and its highest was $327.16 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Jul 30, 2024 which is in 82 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on May 02, 2024. The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.879 by $0.081.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.25 which represents an annual dividend yield of 2.88%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is $4.98.
How many shares outstanding does Amgen have?
Amgen has 536,434,700 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $3.96 in its last earnings report, beating expectations of $3.879. Following the earnings report the stock price went up 11.818%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 4B.
---
Amgen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$321.29 (4.55% Upside)
$321.29 (4.55% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 219.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.23%
12-Months-Change
Fundamentals
Return on Equity
72.57%
Trailing 12-Months
Asset Growth
4.80%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMGN Company Deck
---
AMGN Earnings Call
Q1 2024
0:00 / 0:00
---
AMGN Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
AMGN Stock 12 Month Forecast
Average Price Target
$321.29
▲(4.55% Upside)
Technical Analysis
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
23/28 ratings generated profit
1 Year Average Return
+15.80%
reiterated a buy rating 6 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 82.14% of your transactions generating a profit, with an average return of +15.80% per trade.
---